We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+17.36%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.98B
AUM Growth
+$266M
Cap. Flow
+$123M
Cap. Flow %
6.23%
Top 10 Hldgs %
54.68%
Holding
148
New
19
Increased
38
Reduced
28
Closed
8

Top Buys

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$35.4M
2
TITN icon
Titan Machinery
TITN
+$24.4M
3
BKSY icon
BlackSky Technology
BKSY
+$19.4M
4
CRMT icon
America's Car Mart
CRMT
+$13.5M
5
PWSC
PowerSchool Holdings, Inc.
PWSC
+$13.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$17.8M
2
IMAX icon
IMAX
IMAX
+$10.2M
3
BVS icon
Bioventus
BVS
+$8.54M
4
ESTA icon
Establishment Labs
ESTA
+$6.68M
5
RDNW
RideNow Group
RDNW
+$5.58M

Sector Composition

Rank Sector Weight
1 Healthcare 41.22%
2 Consumer Discretionary 6.49%
3 Communication Services 3.21%
4 Financials 3.01%
5 Industrials 2.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LADR
126
Ladder Capital
LADR
$1.25B
$297K 0.02%
25,631
– –
EVOK
127
DELISTED
Evoke Pharma
EVOK
$268K 0.01%
56,249
-1
-0% -$5
BMTX
128
DELISTED
BM Technologies, Inc.
BMTX
$259K 0.01%
76,034
– –
FBIO icon
129
Fortress Biotech
FBIO
$88M
$221K 0.01%
153,152
– –
XGN icon
130
Exagen
XGN
$166M
$192K 0.01%
62,116
+2,800
+5% +$7.25K
KOD icon
131
Kodiak Sciences
KOD
$2.68B
$180K 0.01%
+68,857
New +$183K
LUCD icon
132
Lucid Diagnostics
LUCD
$184M
$103K 0.01%
126,362
– –
TACT icon
133
Transact Technologies
TACT
$58.1M
$97.8K ﹤0.01%
20,123
– –
APTO
134
DELISTED
Aptose Biosciences, Inc.
APTO
$31.8K ﹤0.01%
2,578
– –
GFAIW icon
135
Guardforce AI Warrant
GFAIW
$60K
$26.2K ﹤0.01%
154,205
– –
RNLX
136
DELISTED
Renalytix plc American Depositary Shares
RNLX
$24.6K ﹤0.01%
117,644
– –
LMND.WS
137
DELISTED
Lemonade Inc Warrants
LMND.WS
$16.2K ﹤0.01%
+507,460
New +$21.4K
HURA
138
TuHURA Biosciences
HURA
$150M
$15.6K ﹤0.01%
+2,279
New +$17K
TCBPW
139
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$4.28K ﹤0.01%
235,294
– –
PERF.WS
140
DELISTED
Perfect Corp Warrants
PERF.WS
$1.13K ﹤0.01%
+16,075
New +$1.2K
ANTX icon
141
AN2 Therapeutics
ANTX
$216M
– –
-98,278
Closed -$211K
AVDL
142
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-350,000
Closed -$4.92M
DXPE icon
143
DXP Enterprises
DXPE
$3.03B
– –
-103,206
Closed -$4.73M
ENVA icon
144
Enova International
ENVA
$6.41B
– –
-55,999
Closed -$4.34M
IWM icon
145
CALL
iShares Russell 2000 ETF
IWM
$81.8B
– –
-300,000
Closed -$60.9M
PWP icon
146
Perella Weinberg Partners
PWP
$1.32B
– –
-265,474
Closed -$4.31M
NKLA
147
DELISTED
Nikola Corporation Common Stock
NKLA
– –
-99,999
Closed -$819K
CONN
148
DELISTED
Conn's Inc.
CONN
– –
-1,973,315
Closed -$2.18M
2 3 4 5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Nantahala Capital Management held 148 positions worth $1.98B, up 16% from $1.71B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Nantahala Capital Management deployed $123M of net new capital in Q3 2024, opening 19 new positions and adding to 38 existing holdings. Its largest new stake was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 40% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Pathward Financial, an estimated $17.8M trimmed.

  • Nantahala Capital Management's largest Q3 2024 buy was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.
  • Nantahala Capital Management added most to America's Car Mart in Q3 2024, an estimated $13.5M increase.
  • Nantahala Capital Management's biggest Q3 2024 reduction was Pathward Financial, cutting an estimated $17.8M.
  • Nantahala Capital Management fully exited Avadel Pharmaceuticals in Q3 2024, selling an estimated $4.92M.
  • Nantahala Capital Management's ten largest holdings make up 55% of its $1.98B portfolio in Q3 2024.
  • Nantahala Capital Management opened 19 new positions and closed 8 in Q3 2024.
  • Nantahala Capital Management's portfolio value rose 16% quarter-over-quarter to $1.98B.

Based on Nantahala Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.